Glenmark Life Sciences Limited
Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and m… Read more
Market Cap & Net Worth: Glenmark Life Sciences Limited (GLS)
Glenmark Life Sciences Limited (NSE:GLS) has a market capitalization of $1.56 Billion (₹134.86 Billion) as of March 19, 2026. Listed on the NSE stock exchange, this India-based company holds position #11514 globally and #491 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Glenmark Life Sciences Limited's stock price ₹1100.60 by its total outstanding shares 122533000 (122.53 Million).
Glenmark Life Sciences Limited Market Cap History: 2021 to 2025
Glenmark Life Sciences Limited's market capitalization history from 2021 to 2025. Data shows growth from $799.24 Million to $1.56 Billion (15.22% CAGR).
Index Memberships
Glenmark Life Sciences Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$535.73 Billion | 0.07% | #283 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$1.32 Trillion | 0.03% | #420 of 750 |
Weight: Glenmark Life Sciences Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Glenmark Life Sciences Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Glenmark Life Sciences Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.06x
Glenmark Life Sciences Limited's market cap is 0.06 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.30x
Glenmark Life Sciences Limited's market cap is 0.30 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $799.24 Million | $18.85 Billion | $3.52 Billion | 0.04x | 0.23x |
| 2022 | $545.23 Million | $21.23 Billion | $4.19 Billion | 0.03x | 0.13x |
| 2023 | $929.64 Million | $21.61 Billion | $4.67 Billion | 0.04x | 0.20x |
| 2024 | $1.39 Billion | $22.83 Billion | $4.71 Billion | 0.06x | 0.30x |
Competitor Companies of GLS by Market Capitalization
Companies near Glenmark Life Sciences Limited in the global market cap rankings as of March 19, 2026.
Key companies related to Glenmark Life Sciences Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Glenmark Life Sciences Limited Historical Marketcap From 2021 to 2025
Between 2021 and today, Glenmark Life Sciences Limited's market cap moved from $799.24 Million to $ 1.56 Billion, with a yearly change of 15.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | ₹1.56 Billion | +11.91% |
| 2024 | ₹1.39 Billion | +49.68% |
| 2023 | ₹929.64 Million | +70.50% |
| 2022 | ₹545.23 Million | -31.78% |
| 2021 | ₹799.24 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Glenmark Life Sciences Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.56 Billion USD |
| MoneyControl | $1.56 Billion USD |
| MarketWatch | $1.56 Billion USD |
| marketcap.company | $1.56 Billion USD |
| Reuters | $1.56 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.